Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Indirect Comparison Analysis of Risankizumab and Icotrokinra Efficacy in Adults with Moderate-to-Severe Plaque Psoriasis

  • By

  • Jeffrey Crowley

  • Eingun James Song

  • Linda Stein-Gold

  • Paolo Gisondi

  • Christopher G. Bunick

  • Vishvas Garg

  • Emanuele Leoncini

  • Blair Kaplan

  • Richard Ta

  • Bang Truong

  • Dolly Sharma

  • Bruce Strober

  • July 2, 2026

Share

Original Source(s)

Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis

  • by Jeffrey Crowley, Eingun James Song, Linda Stein-Gold, Paolo Gisondi, Christopher G. Bunick, Vishvas Garg, Emanuele Leoncini, Blair Kaplan, Richard Ta, Bang Truong, Dolly Sharma, Bruce Strober

  • July 2, 2026

Related Content

Understanding Social Drivers of Health Among US Adults with Psoriasis from Different Races and Ethnicities

Pediatric Psoriasis: Comorbidities, Treatment Challenges and Unmet Needs

Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival